AR051334A1 - Derivados de 2- amido-4-feniltiazol - Google Patents
Derivados de 2- amido-4-feniltiazolInfo
- Publication number
- AR051334A1 AR051334A1 ARP050104349A ARP050104349A AR051334A1 AR 051334 A1 AR051334 A1 AR 051334A1 AR P050104349 A ARP050104349 A AR P050104349A AR P050104349 A ARP050104349 A AR P050104349A AR 051334 A1 AR051334 A1 AR 051334A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- group
- cycloalkyl
- trifluoro
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000005336 allyloxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones farmacéuticas que los contienen, usos terapéuticos y método de preparacion. Reivindicacion 1: Compuesto de formula (1), en la cual: R1 representa un átomo de hidrogeno o de halogeno, un grupo alquilo-C1-4, trifluoro-alquilo-C1-4, hidroxilo, alcoxi-C1-4, trifluoro-alcoxi-C1-4, cicloalquil-C3-10-alcoxi-C1-4, cicloalquiloxi-C3-10, aliloxi, alquiltio-C1-4; R2 representa un átomo de hidrogeno o de halogeno, un grupo hidroxilo, alquilo-C1-4, trifluoro-alquilo-C1-4, perfluoro- alquilo-C1-4, cicloalquilo-C3-10, alcoxi-C1-4, cicloalquil-C3-10-alcoxi-C1-4, cicloalquiloxi-C3-10, aliloxi, cicloalquil-C3-8-alquilo-C1-4; Y representa un átomo de hidrogeno o un halogeno; y R3 representa: un grupo fenilo, sustituido por uno o varios átomos de halogeno y/o por uno o varios grupos; alquilo-C1-6; alcoxi-C1-6; -NO2; ciano; -COR4; -SO2R4; -CO2R4, en el cual R4 representa un grupo alquilo-C1-4; y -(CH2)qNR5R6 en el cual R5 y r6 representan independientemente el uno del otro un átomo de hidrogeno, un grupo alquilo-C1-4 o R5 y R6 forman juntos con el átomo de nitrogeno al cual están unidos un grupo cicloalquilo de 5 o 6 eslabones y q representan 0, 1 o 2; un grupo heterociclo eventualmente sustituido por uno o varios halogenos y/o por uno o varios grupos: alquilo-C1-4; hidroxilo; alcoxi-C1-4; ciano; morfolino; trifluoro-alquilo-C1-4; -COR4; -SO2R4, en el cual R4 es tal como se define en lo que se precede, -(CH2)qNR5R6, en el cual R5, R6 y q son tales como se definen en lo que precede; fenilo; piridina; y -SCH3; estando el o los átomos de nitrogeno del grupo heterocíclico eventualmente sustituido por un grupo alquilo-C1-4; estando el o los átomos de nitrogeno del grupo heterocíclico eventualmente bajo su forma de N-oxido; un grupo heterobicíclico eventualmente sustituido por uno o varios halogenos y/o por uno o varios grupos hidroxilos, alquilo-C1-4 o alcoxi-C1-4; m representa 2, 3 o 4; n representa 0, 1 o 2; y p representa 0, 1, 2 o 3; en el estado de base o de sal de adicion a un ácido farmacéuticamente aceptable, en estado de hidratos o de solvatos, así como en forma de enantiomeros, de diastereoisomeros y su mezcla.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0411083A FR2876692B1 (fr) | 2004-10-19 | 2004-10-19 | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051334A1 true AR051334A1 (es) | 2007-01-03 |
Family
ID=34950743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104349A AR051334A1 (es) | 2004-10-19 | 2005-10-18 | Derivados de 2- amido-4-feniltiazol |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7598392B2 (es) |
| EP (1) | EP1807421B1 (es) |
| JP (1) | JP2008517042A (es) |
| KR (1) | KR20070085395A (es) |
| CN (1) | CN101065376A (es) |
| AR (1) | AR051334A1 (es) |
| AT (1) | ATE502035T1 (es) |
| AU (1) | AU2005296958A1 (es) |
| BR (1) | BRPI0518231A2 (es) |
| CA (1) | CA2584774A1 (es) |
| DE (1) | DE602005026964D1 (es) |
| EA (1) | EA200700901A1 (es) |
| EC (1) | ECSP077402A (es) |
| FR (1) | FR2876692B1 (es) |
| GT (1) | GT200500292A (es) |
| IL (1) | IL182624A0 (es) |
| MA (1) | MA29017B1 (es) |
| MX (1) | MX2007004740A (es) |
| NO (1) | NO20072515L (es) |
| PA (1) | PA8649901A1 (es) |
| PE (1) | PE20060585A1 (es) |
| SV (1) | SV2006002274A (es) |
| TN (1) | TNSN07145A1 (es) |
| TW (1) | TW200630364A (es) |
| UY (1) | UY29169A1 (es) |
| WO (1) | WO2006042954A1 (es) |
| ZA (1) | ZA200703876B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| TW200730476A (en) * | 2005-12-12 | 2007-08-16 | Genelabs Tech Inc | N-(5-membered aromatic ring)-amido anti-viral compounds |
| FR2895989B1 (fr) | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| WO2009076404A1 (en) * | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| EP2280766A1 (en) * | 2007-12-11 | 2011-02-09 | CytoPathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| PE20110105A1 (es) | 2008-07-15 | 2011-02-25 | Novartis Ag | Derivados de heteroarilo como inhibidores de dgat1 |
| EP4015504A1 (en) * | 2008-12-22 | 2022-06-22 | ChemoCentryx, Inc. | C5ar antagonists |
| CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| US9464081B2 (en) | 2012-06-28 | 2016-10-11 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| EP2867225B1 (en) | 2012-06-28 | 2017-08-09 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| ES2710491T3 (es) | 2012-06-28 | 2019-04-25 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| CN104640855B (zh) | 2012-06-28 | 2017-08-29 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| WO2014002053A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| CN104684910B (zh) | 2012-07-12 | 2016-10-12 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| MX2022010944A (es) | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
| WO2023028235A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN118019739A (zh) | 2021-08-25 | 2024-05-10 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| KR20240140019A (ko) * | 2023-03-15 | 2024-09-24 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 약학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2146898A (en) * | 1937-12-06 | 1939-02-14 | Int Harvester Co | Potato digger |
| FR2406634A1 (fr) | 1977-10-19 | 1979-05-18 | Fabre Sa Pierre | Immunostimulants derives d'amino thiazoles |
| FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| EP0519449A1 (en) | 1991-06-21 | 1992-12-23 | Boehringer Mannheim Italia S.P.A. | 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract |
| US6506751B1 (en) | 1999-11-12 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Thiazolidinone compounds useful as chemokine inhibitors |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| KR20030064852A (ko) | 2000-12-22 | 2003-08-02 | 이시하라 산교 가부시끼가이샤 | 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제 |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| AR044098A1 (es) | 2003-04-30 | 2005-08-24 | Hoffmann La Roche | Derivados de anilina, su elaboracion, composiciones farmaceuticas y su uso para elaborar medicamentos para el tratamiento del cancer |
| FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| BRPI0519288A2 (pt) | 2004-12-24 | 2009-01-06 | Astrazeneca Ab | compostos heterocÍclicos como antagonistas de ccr2b |
| FR2895989B1 (fr) | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
-
2004
- 2004-10-19 FR FR0411083A patent/FR2876692B1/fr not_active Expired - Fee Related
-
2005
- 2005-10-17 DE DE602005026964T patent/DE602005026964D1/de not_active Expired - Lifetime
- 2005-10-17 MX MX2007004740A patent/MX2007004740A/es not_active Application Discontinuation
- 2005-10-17 AU AU2005296958A patent/AU2005296958A1/en not_active Withdrawn
- 2005-10-17 UY UY29169A patent/UY29169A1/es not_active Application Discontinuation
- 2005-10-17 BR BRPI0518231-0A patent/BRPI0518231A2/pt not_active IP Right Cessation
- 2005-10-17 GT GT200500292A patent/GT200500292A/es unknown
- 2005-10-17 WO PCT/FR2005/002565 patent/WO2006042954A1/fr not_active Ceased
- 2005-10-17 ZA ZA200703876A patent/ZA200703876B/xx unknown
- 2005-10-17 CN CNA2005800396968A patent/CN101065376A/zh active Pending
- 2005-10-17 JP JP2007537324A patent/JP2008517042A/ja active Pending
- 2005-10-17 EP EP05809089A patent/EP1807421B1/fr not_active Expired - Lifetime
- 2005-10-17 KR KR1020077011308A patent/KR20070085395A/ko not_active Withdrawn
- 2005-10-17 AT AT05809089T patent/ATE502035T1/de not_active IP Right Cessation
- 2005-10-17 CA CA002584774A patent/CA2584774A1/fr not_active Abandoned
- 2005-10-17 EA EA200700901A patent/EA200700901A1/ru unknown
- 2005-10-18 AR ARP050104349A patent/AR051334A1/es unknown
- 2005-10-18 TW TW094136365A patent/TW200630364A/zh unknown
- 2005-10-18 PA PA20058649901A patent/PA8649901A1/es unknown
- 2005-10-19 SV SV2005002274A patent/SV2006002274A/es unknown
- 2005-10-19 PE PE2005001227A patent/PE20060585A1/es not_active Application Discontinuation
-
2007
- 2007-04-17 IL IL182624A patent/IL182624A0/en unknown
- 2007-04-18 US US11/736,770 patent/US7598392B2/en not_active Expired - Fee Related
- 2007-04-18 EC EC2007007402A patent/ECSP077402A/es unknown
- 2007-04-19 TN TNP2007000145A patent/TNSN07145A1/fr unknown
- 2007-05-11 MA MA29894A patent/MA29017B1/fr unknown
- 2007-05-16 NO NO20072515A patent/NO20072515L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SV2006002274A (es) | 2006-06-28 |
| UY29169A1 (es) | 2006-05-31 |
| CA2584774A1 (fr) | 2006-04-27 |
| EP1807421A1 (fr) | 2007-07-18 |
| ECSP077402A (es) | 2007-05-30 |
| WO2006042954A8 (fr) | 2008-03-13 |
| US7598392B2 (en) | 2009-10-06 |
| MA29017B1 (fr) | 2007-11-01 |
| EP1807421B1 (fr) | 2011-03-16 |
| EA200700901A1 (ru) | 2007-10-26 |
| IL182624A0 (en) | 2007-07-24 |
| PE20060585A1 (es) | 2006-08-18 |
| WO2006042954A1 (fr) | 2006-04-27 |
| US20070259847A1 (en) | 2007-11-08 |
| CN101065376A (zh) | 2007-10-31 |
| NO20072515L (no) | 2007-06-28 |
| BRPI0518231A2 (pt) | 2008-11-11 |
| PA8649901A1 (es) | 2006-06-02 |
| FR2876692A1 (fr) | 2006-04-21 |
| AU2005296958A1 (en) | 2006-04-27 |
| JP2008517042A (ja) | 2008-05-22 |
| ATE502035T1 (de) | 2011-04-15 |
| MX2007004740A (es) | 2007-06-18 |
| DE602005026964D1 (de) | 2011-04-28 |
| KR20070085395A (ko) | 2007-08-27 |
| GT200500292A (es) | 2006-05-11 |
| ZA200703876B (en) | 2008-12-31 |
| TW200630364A (en) | 2006-09-01 |
| FR2876692B1 (fr) | 2007-02-23 |
| TNSN07145A1 (fr) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051334A1 (es) | Derivados de 2- amido-4-feniltiazol | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR120855A1 (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR078168A1 (es) | Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119 | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR061106A1 (es) | Pteridinas sustituidas y composiciones farmaceuticas que las contienen. | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |